Inclisiran and Elevated CPK
Based on the available evidence from major clinical trials and FDA labeling, inclisiran does NOT cause clinically significant elevations in creatine phosphokinase (CPK) levels. The safety profile of inclisiran is comparable to placebo with respect to muscle-related adverse events and CPK elevations.
Evidence from Clinical Trials
In the pooled analysis of 3,660 patients from the ORION-9, ORION-10, and ORION-11 phase 3 trials, safety was similar between inclisiran and placebo groups 1. The primary adverse events reported were injection site reactions (5.0% vs 0.7% with placebo), which were predominantly mild and none were severe or persistent 1.
The most recent comprehensive safety analysis included 3,576 patients treated with inclisiran for up to 6 years, demonstrating that elevations of creatine kinase accrued at a comparable rate between inclisiran and placebo groups 2. Kaplan-Meier analyses showed no difference in muscle events or CK elevations between groups for up to 1.5 years, with similar trends continuing for inclisiran beyond this period 2.
Guideline Perspectives
The 2025 AACE Clinical Practice Guideline specifically notes that adverse events reported in inclisiran trials included injection site reactions and bronchitis, with no mention of CPK elevation as a significant concern 3. The 2022 ACC Expert Consensus similarly emphasizes that "Safety was otherwise similar in both groups" beyond the mild injection site reactions 1.
Clinical Context
This favorable muscle safety profile is particularly relevant because:
- Inclisiran is often considered for statin-intolerant patients, many of whom have experienced muscle symptoms or CPK elevations with statins
- Unlike statins, inclisiran works through RNA interference to reduce PCSK9 production in hepatocytes, not through direct muscle effects 3
- The mechanism of action (siRNA targeting hepatic PCSK9 mRNA) does not involve pathways typically associated with muscle toxicity 4
Comparative Safety
A network meta-analysis comparing PCSK9 inhibitors found that evolocumab showed the best results for both muscle symptoms and CK >3× ULN, but inclisiran still demonstrated a favorable safety profile without significant muscle-related adverse events 5. Real-world evidence suggests inclisiran may have different safety tendencies compared to monoclonal antibody PCSK9 inhibitors, but muscle toxicity is not among the concerning differences 6.
Practical Recommendation
You can safely use inclisiran in patients with concerns about CPK elevation, including those with prior statin-related muscle symptoms. The drug does not require routine CPK monitoring based on its mechanism or clinical trial safety data. However, if a patient on inclisiran develops unexplained muscle symptoms, standard evaluation including CPK measurement would be appropriate—not because inclisiran causes this, but as part of routine clinical assessment for any patient with muscle complaints.
The twice-yearly dosing schedule (after initial doses at baseline and 3 months) makes inclisiran particularly attractive for patients with medication adherence issues or those who have discontinued statins due to muscle-related side effects 3.